Recent Updates
Recently added Catalysts
RAPP Positive Sentiment Score: 60/100

Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein (TARPγ8): Impact on RNS Long Episodes and Focal Seizures

Key Takeaway: The article discusses RAP-219, a novel negative allosteric modulator targeting TARPγ8, which may provide efficacy in treating RNS long episodes and focal seizures. The research is led by a team of experienced medical professionals, highlighting the potential of this first-in-class therapy. The implications for seizure management could be significant.
Price reaction · baseline $28.7 (2025-12-04 close) · hit pre-market · 2 other RAPP headline(s) in the window, move may be shared
day 0 close · peak
+2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential first-in-class treatment for seizures.
  • Focus on negative allosteric modulation may offer new therapeutic avenues.
  • Involvement of multiple experienced researchers enhances credibility.

Full Press Release Details

William W. Motley, MD, D.Phil; Imran H. Quraishi, MD, PhD; Neal Nolan, MD; Daniel Friedman, MD; Patrick Landazuri, MD; Vikram R. Rao, MD; Kathryn A. Davis, MD; Bradley S. Galer, MD; Nancy Wyant, BA; Martha J. Morrell, MD; Arnold R. Gammaitoni, PharmD; Jacqueline A. French, MD

Frequently Asked Questions

What is RAP-219?

RAP-219 is a potential first-in-class negative allosteric modulator targeting TARPγ8.

What conditions does RAP-219 aim to treat?

It aims to treat RNS long episodes and focal seizures.

Who are the researchers involved in the study?

The study involves a team of experienced medical professionals.

What is the significance of TARPγ8?

TARPγ8 is a protein that RAP-219 targets to potentially modulate seizure activity.

Last updated: Dec 5, 2025